Minister of Health Aaron Motsoaledi has confirmed that Lenacapavir, the anti-retroviral medicine to protect against HIV, will be rolled out from 5 June.

Delivering his budget vote in Parliament on Wednesday, Motsoaledi said stocks will be delivered to 360 health facilities in high-burden districts.

But he’s warned that cervical cancer is now fast becoming the country’s new pandemic.

In South Africa, 65% of all women diagnosed with cervical cancer are also HIV positive.

ALSO READ:

Health Dept welcomes arrival of new HIV prevention medicine Lenacapavir

Lenacapavir rollout: US-South Africa collaboration strengthens fight against HIV

Motsoaledi hails Lenacapavir as game-changer for SA's fight against HIV/AIDS

With one of the highest HIV-prevalence rates in the world, Motsoaledi said eradicating HIV/AIDS as a public health threat is within reach for South Africa.

The six-monthly Lenacapavir injection, which is designed to prevent the transmission of HIV, will be administered to specific categories of the population, which include adolescent girls and young women up to the age of 24.

Pregnant and breastfeeding mothers, female sex workers, men who have sex with men, transgender people and injecting drug users will also be targeted.

Motsoaledi said President Cyril Ramaphosa will officiate the launch of the drug in Mpumalanga.

“As a country, we know what is at stake because we have achieved results, which are there for everybody to see.”

But Motsoaledi said cervical cancer is now the second biggest killer of women, after breast cancer.

He said it’s imperative that girls between the ages of 9 and 15 receive the HPV vaccine to reach new targets set by the World Health Organization (WHO).